**What is claimed is:**

1. An antibody or an antigen-binding fragment thereof that specifically binds to RSV, comprising:

(1) a CDR-H1 set forth in SEQ ID NO: 1, a CDR-H2 set forth in SEQ ID NO: 2, a CDR-H3 set forth in SEQ ID NO: 3, a CDR-L1 set forth in SEQ ID NO: 4, a CDR-L2 set forth in SEQ ID NO: 5, and a CDR-L3 set forth in SEQ ID NO: 6;

(2) a CDR-H1 set forth in SEQ ID NO: 9, a CDR-H2 set forth in SEQ ID NO: 10, a CDR-H3 set forth in SEQ ID NO: 11, a CDR-L1 set forth in SEQ ID NO: 12, a CDR-L2 set forth in SEQ ID NO: 13, and a CDR-L3 set forth in SEQ ID NO: 14;

(3) a CDR-H1 set forth in SEQ ID NO: 17, a CDR-H2 set forth in SEQ ID NO: 18, a CDR-H3 set forth in SEQ ID NO: 19, a CDR-L1 set forth in SEQ ID NO: 20, a CDR-L2 set forth in SEQ ID NO: 21, and a CDR-L3 set forth in SEQ ID NO: 22;

(4) a CDR-H1 set forth in SEQ ID NO: 25, a CDR-H2 set forth in SEQ ID NO: 26, a CDR-H3 set forth in SEQ ID NO: 27, a CDR-L1 set forth in SEQ ID NO: 28, a CDR-L2 set forth in SEQ ID NO: 29, and a CDR-L3 set forth in SEQ ID NO: 30;

(5) a CDR-H1 set forth in SEQ ID NO: 33, a CDR-H2 set forth in SEQ ID NO: 34, a CDR-H3 set forth in SEQ ID NO: 35, a CDR-L1 set forth in SEQ ID NO: 36, a CDR-L2 set forth in SEQ ID NO: 37, and a CDR-L3 set forth in SEQ ID NO: 38;

(6) a CDR-H1 set forth in SEQ ID NO: 41, a CDR-H2 set forth in SEQ ID NO: 42, a CDR-H3 set forth in SEQ ID NO: 43, a CDR-L1 set forth in SEQ ID NO: 44, a CDR-L2 set forth in SEQ ID NO: 45, and a CDR-L3 set forth in SEQ ID NO: 46;

(7) a CDR-H1 set forth in SEQ ID NO: 49, a CDR-H2 set forth in SEQ ID NO: 50, a CDR-H3 set forth in SEQ ID NO: 51, a CDR-L1 set forth in SEQ ID NO: 52, a CDR-L2 set forth in SEQ ID NO: 53, and a CDR-L3 set forth in SEQ ID NO: 54;

(8) a CDR-H1 set forth in SEQ ID NO: 57, a CDR-H2 set forth in SEQ ID NO: 58, a CDR-H3 set forth in SEQ ID NO: 59, a CDR-L1 set forth in SEQ ID NO: 60, a CDR-L2 set forth in SEQ ID NO: 61, and a CDR-L3 set forth in SEQ ID NO: 62;

(9) a CDR-H1 set forth in SEQ ID NO: 65, a CDR-H2 set forth in SEQ ID NO: 66, a CDR-H3 set forth in SEQ ID NO: 67, a CDR-L1 set forth in SEQ ID NO: 68, a CDR-L2 set forth in SEQ ID NO: 69, and a CDR-L3 set forth in SEQ ID NO: 70;

(10) a CDR-H1 set forth in SEQ ID NO: 73, a CDR-H2 set forth in SEQ ID NO: 74, a CDR-

H3 set forth in SEQ ID NO: 75, a CDR-L1 set forth in SEQ ID NO: 76, a CDR-L2 set forth in SEQ ID NO: 77, and a CDR-L3 set forth in SEQ ID NO: 78;

(11) a CDR-H1 set forth in SEQ ID NO: 81, a CDR-H2 set forth in SEQ ID NO: 82, a CDR-H3 set forth in SEQ ID NO: 83, a CDR-L1 set forth in SEQ ID NO: 84, a CDR-L2 set forth in SEQ ID NO: 85, and a CDR-L3 set forth in SEQ ID NO: 86;

(12) a CDR-H1 set forth in SEQ ID NO: 89, a CDR-H2 set forth in SEQ ID NO: 90, a CDR-H3 set forth in SEQ ID NO: 91, a CDR-L1 set forth in SEQ ID NO: 92, a CDR-L2 set forth in SEQ ID NO: 93, and a CDR-L3 set forth in SEQ ID NO: 94;

(13) a CDR-H1 set forth in SEQ ID NO: 97, a CDR-H2 set forth in SEQ ID NO: 98, a CDR-H3 set forth in SEQ ID NO: 99, a CDR-L1 set forth in SEQ ID NO: 100, a CDR-L2 set forth in SEQ ID NO: 101, and a CDR-L3 set forth in SEQ ID NO: 102;

(14) a CDR-H1 set forth in SEQ ID NO: 105, a CDR-H2 set forth in SEQ ID NO: 106, a CDR-H3 set forth in SEQ ID NO: 107, a CDR-L1 set forth in SEQ ID NO: 108, a CDR-L2 set forth in SEQ ID NO: 109, and a CDR-L3 set forth in SEQ ID NO: 110;

(15) a CDR-H1 set forth in SEQ ID NO: 113, a CDR-H2 set forth in SEQ ID NO: 114, a CDR-H3 set forth in SEQ ID NO: 115, a CDR-L1 set forth in SEQ ID NO: 116, a CDR-L2 set forth in SEQ ID NO: 117, and a CDR-L3 set forth in SEQ ID NO: 118;

(16) a CDR-H1 set forth in SEQ ID NO: 121, a CDR-H2 set forth in SEQ ID NO: 122, a CDR-H3 set forth in SEQ ID NO: 123, a CDR-L1 set forth in SEQ ID NO: 124, a CDR-L2 set forth in SEQ ID NO: 125, and a CDR-L3 set forth in SEQ ID NO: 126;

(17) a CDR-H1 set forth in SEQ ID NO: 129, a CDR-H2 set forth in SEQ ID NO: 130, a CDR-H3 set forth in SEQ ID NO: 131, a CDR-L1 set forth in SEQ ID NO: 132, a CDR-L2 set forth in SEQ ID NO: 133, and a CDR-L3 set forth in SEQ ID NO: 134;

(18) a CDR-H1 set forth in SEQ ID NO: 137, a CDR-H2 set forth in SEQ ID NO: 138, a CDR-H3 set forth in SEQ ID NO: 139, a CDR-L1 set forth in SEQ ID NO: 140, a CDR-L2 set forth in SEQ ID NO: 141, and a CDR-L3 set forth in SEQ ID NO: 142;

(19) a CDR-H1 set forth in SEQ ID NO: 145, a CDR-H2 set forth in SEQ ID NO: 146, a CDR-H3 set forth in SEQ ID NO: 147, a CDR-L1 set forth in SEQ ID NO: 148, a CDR-L2 set forth in SEQ ID NO: 149, and a CDR-L3 set forth in SEQ ID NO: 150;

(20) a CDR-H1 set forth in SEQ ID NO: 153, a CDR-H2 set forth in SEQ ID NO: 154, a CDR-H3 set forth in SEQ ID NO: 155, a CDR-L1 set forth in SEQ ID NO: 156, a CDR-L2 set

forth in SEQ ID NO: 157, and a CDR-L3 set forth in SEQ ID NO: 158;

(21) a CDR-H1 set forth in SEQ ID NO: 161, a CDR-H2 set forth in SEQ ID NO: 162, a CDR-H3 set forth in SEQ ID NO: 163, a CDR-L1 set forth in SEQ ID NO: 164, a CDR-L2 set forth in SEQ ID NO: 165, and a CDR-L3 set forth in SEQ ID NO: 166;

(22) a CDR-H1 set forth in SEQ ID NO: 169, a CDR-H2 set forth in SEQ ID NO: 170, a CDR-H3 set forth in SEQ ID NO: 171, a CDR-L1 set forth in SEQ ID NO: 172, a CDR-L2 set forth in SEQ ID NO: 173, and a CDR-L3 set forth in SEQ ID NO: 174;

(23) a CDR-H1 set forth in SEQ ID NO: 177, a CDR-H2 set forth in SEQ ID NO: 178, a CDR-H3 set forth in SEQ ID NO: 179, a CDR-L1 set forth in SEQ ID NO: 180, a CDR-L2 set forth in SEQ ID NO: 181, and a CDR-L3 set forth in SEQ ID NO: 182; or

(24) a CDR-H1 set forth in SEQ ID NO: 185, a CDR-H2 set forth in SEQ ID NO: 186, a CDR-H3 set forth in SEQ ID NO: 187, a CDR-L1 set forth in SEQ ID NO: 188, a CDR-L2 set forth in SEQ ID NO: 189, and a CDR-L3 set forth in SEQ ID NO: 190.

2. The antibody or the antigen-binding fragment thereof according to claim 1, comprising:

(1) a VH set forth in SEQ ID NO: 7 and a VL set forth in SEQ ID NO: 8;

(2) a VH set forth in SEQ ID NO: 15 and a VL set forth in SEQ ID NO: 16;

(3) a VH set forth in SEQ ID NO: 23 and a VL set forth in SEQ ID NO: 24;

(4) a VH set forth in SEQ ID NO: 31 and a VL set forth in SEQ ID NO: 32;

(5) a VH set forth in SEQ ID NO: 39 and a VL set forth in SEQ ID NO: 40;

(6) a VH set forth in SEQ ID NO: 47 and a VL set forth in SEQ ID NO: 48;

(7) a VH set forth in SEQ ID NO: 55 and a VL set forth in SEQ ID NO: 56;

(8) a VH set forth in SEQ ID NO: 63 and a VL set forth in SEQ ID NO: 64;

(9) a VH set forth in SEQ ID NO: 71 and a VL set forth in SEQ ID NO: 72;

(10) a VH set forth in SEQ ID NO: 79 and a VL set forth in SEQ ID NO: 80;

(11) a VH set forth in SEQ ID NO: 87 and a VL set forth in SEQ ID NO: 88;

(12) a VH set forth in SEQ ID NO: 95 and a VL set forth in SEQ ID NO: 96;

(13) a VH set forth in SEQ ID NO: 103 and a VL set forth in SEQ ID NO: 104;

(14) a VH set forth in SEQ ID NO: 111 and a VL set forth in SEQ ID NO: 112;

(15) a VH set forth in SEQ ID NO: 119 and a VL set forth in SEQ ID NO: 120;

(16) a VH set forth in SEQ ID NO: 127 and a VL set forth in SEQ ID NO: 128;

(17) a VH set forth in SEQ ID NO: 135 and a VL set forth in SEQ ID NO: 136;

(18) a VH set forth in SEQ ID NO: 143 and a VL set forth in SEQ ID NO: 144;

(19) a VH set forth in SEQ ID NO: 151 and a VL set forth in SEQ ID NO: 152;

(20) a VH set forth in SEQ ID NO: 159 and a VL set forth in SEQ ID NO: 160;

(21) a VH set forth in SEQ ID NO: 167 and a VL set forth in SEQ ID NO: 168;

(22) a VH set forth in SEQ ID NO: 175 and a VL set forth in SEQ ID NO: 176;

(23) a VH set forth in SEQ ID NO: 183 and a VL set forth in SEQ ID NO: 184; or

(24) a VH set forth in SEQ ID NO: 191 and a VL set forth in SEQ ID NO: 192.

3. The antibody or the antigen-binding fragment thereof according to claim 1, comprising:

(1) a heavy chain constant region set forth in SEQ ID NO: 201, and

(2) a light chain constant region as set forth in any one of SEQ ID NOs: 193-200.

4. The antibody or the antigen-binding fragment thereof according to claim 1, comprising:

an α heavy chain, a δ heavy chain, an ε heavy chain, a γ heavy chain or a μ heavy chain; and/or

a λ light chain or a κ light chain.

5. The antibody or the antigen-binding fragment thereof according to claim 1, belonging to an IgG1, IgG2, IgG3 or IgG4 subclass.

6. The antibody or the antigen-binding fragment thereof according to claim 1, wherein the antibody or the antigen-binding fragment thereof is:

a full-length antibody; or

an antibody fragment selected from Fv, scFv, Fab, Fab', $F(ab')_2$ and xFab.

7. The antibody or the antigen-binding fragment thereof according to any one of claims 1-6, having one or more of properties of:

(1) being capable of specifically binding to an RSV A2 pre-F protein;

(2) being capable of specifically binding to an RSV A2 pre-F protein with an EC50 value less than 62, 61, 60, 59, 50, 40, 36, 35, 32, 31, 30, 29, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13,

12, 11, 10, 9, 8, 7.5 or 7.2 ng/mL, or with an EC50 value which is (e.g., 1% to 99%, e.g., at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%) less than that of MEDI8897;

(3) being capable of specifically binding to an RSV A2 pre-F protein with a KD value less than 3.3, 2.2, 1.3, 1.0, 0.9, 0.4, 0.3, 0.2, 0.15, 0.07, 0.06 or 0.001 nM, or with a KD value which is (e.g., 1% to 99%, e.g., at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%) less than that of MEDI8897;

(4) being capable of inhibiting RSV (e.g., subgroup A and/or subgroup B) from infecting a host cell;

(5) being capable of inhibiting an RSV subgroup A strain (e.g., A2) from infecting a host cell with an IC50 value less than 100, 90, 80, 70, 60, 50, 45, 40, 35, 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1.5 ng/mL, or with an IC50 value which is (e.g., 1% to 99%, e.g., at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%) less than that of MEDI8897;

(6) being capable of inhibiting an RSV subgroup B strain (e.g., B9320) from infecting a host cell with an IC50 value less than 160, 150, 140, 130, 120, 110, 100, 90, 80, 70, 60, 50, 40, 30, 20, 15, 10, 9, 8, 7, 6, 5, 4 or 3 ng/mL, or with an IC50 value which is (e.g., 1% to 99%, e.g., at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%) less than that of MEDI8897;

(7) being capable of inhibiting an RSV subgroup B strain (e.g., B18537) from infecting a host cell with an IC50 value less than 80, 70, 60, 50, 45, 40, 35, 30, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 ng/mL, or with an IC50 value which is (e.g., 1% to 99%, e.g., at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%) less than that of MEDI8897;

(8) being capable of competing for or inhibiting the binding of MEDI8897 to an RSV A2 pre-F protein;

(9) being capable of inhibiting the binding of MEDI8897 to an RSV A2 pre-F protein by 1% to 100%, e.g., at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%;

(10) being capable of competing for or inhibiting the binding of MK-1654 to an RSV A2 pre-

F protein;

(11) being capable of inhibiting the binding of MK-1654 to an RSV A2 pre-F protein by 1% to 100%, e.g., at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%;

(12) being capable of competing for or inhibiting the binding of Motavizumab to an RSV A2 pre-F protein;

(13) being capable of inhibiting the binding of Motavizumab to an RSV A2 pre-F protein by 1% to 100%, e.g., at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%;

(14) being capable of competing for or inhibiting the binding of MPE8 to an RSV A2 pre-F protein;

(15) being capable of inhibiting the binding of MPE8 to an RSV A2 pre-F protein by 1% to 100%, e.g., at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%;

(16) being capable of binding to an epitope Ø of an RSV A2 pre-F protein;

(17) being capable of binding to an epitope IV of an RSV A2 pre-F protein;

(18) being capable of binding to epitopes Ø and IV of an RSV A2 pre-F protein;

(19) being capable of binding to an epitope II of an RSV A2 pre-F protein;

(20) being capable of binding to an epitope III of an RSV A2 pre-F protein; and/or

(21) being capable of binding to epitopes II and III of an RSV A2 pre-F protein.

8. A polynucleotide encoding the antibody or the antigen-binding fragment thereof according to any one of claims 1-7.

9. The polynucleotide according to claim 8, comprising:

(1) SEQ ID NOs: 202 and 203;

(2) SEQ ID NOs: 204 and 205;

(3) SEQ ID NOs: 206 and 207;

(4) SEQ ID NOs: 208 and 209;

(5) SEQ ID NOs: 210 and 211;

(6) SEQ ID NOs: 212 and 213;

(7) SEQ ID NOs: 214 and 215;

(8) SEQ ID NOs: 216 and 217;

(9) SEQ ID NOs: 218 and 219;

(10) SEQ ID NOs: 220 and 221;

(11) SEQ ID NOs: 222 and 223;

(12) SEQ ID NOs: 224 and 225;

(13) SEQ ID NOs: 226 and 227;

(14) SEQ ID NOs: 228 and 229;

(15) SEQ ID NOs: 230 and 231;

(16) SEQ ID NOs: 232 and 233;

(17) SEQ ID NOs: 234 and 235;

(18) SEQ ID NOs: 236 and 237;

(19) SEQ ID NOs: 238 and 239;

(20) SEQ ID NOs: 240 and 241;

(21) SEQ ID NOs: 242 and 243;

(22) SEQ ID NOs: 244 and 245;

(23) SEQ ID NOs: 246 and 247; or

(24) SEQ ID NOs: 248 and 249.

10. A vector comprising the polynucleotide according to claim 8 or 9.

11. A host cell comprising the polynucleotide according to claim 8 or 9 or the vector according to claim 10.

12. The host cell according to claim 11, being a eukaryotic cell.

13. The host cell according to claim 12, being a CHO cell.

14. A method for generating an antibody or an antigen-binding fragment thereof, comprising:

(a) culturing the host cell according to any one of claims 11-13 under conditions suitable for expression of the antibody or the antigen-binding fragment thereof, and

(b) optionally, recovering the antibody or the antigen-binding fragment thereof.

15. A composition comprising the antibody or the antigen-binding fragment thereof according to any one of claims 1-7.

16. The antibody or the antigen-binding fragment thereof according to any one of claims 1-7 or the composition according to claim 15, for use as a medicament.

17. The antibody or the antigen-binding fragment thereof according to any one of claims 1-7 or the composition according to claim 15, for use in the treatment of a disease.

18. The antibody or the antigen-binding fragment thereof or the composition according to claim 17, wherein the disease is a lower respiratory tract infection.

19. Use of the antibody or the antigen-binding fragment thereof according to any one of claims 1-7 or the composition according to claim 15 for the manufacture of a medicament for treating a disease.

20. The use according to claim 19, wherein the disease is a lower respiratory tract infection.